1. Home
  2. NBR vs VIR Comparison

NBR vs VIR Comparison

Compare NBR & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nabors Industries Ltd.

NBR

Nabors Industries Ltd.

HOLD

Current Price

$52.68

Market Cap

746.4M

Sector

Energy

ML Signal

HOLD

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

HOLD

Current Price

$6.01

Market Cap

825.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBR
VIR
Founded
1952
2016
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
746.4M
825.0M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
NBR
VIR
Price
$52.68
$6.01
Analyst Decision
Hold
Strong Buy
Analyst Count
8
11
Target Price
$50.75
$25.73
AVG Volume (30 Days)
389.3K
2.2M
Earning Date
02-11-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
14.43
N/A
Revenue
$3,116,983,000.00
$16,860,000.00
Revenue This Year
$9.62
N/A
Revenue Next Year
$0.84
$48.05
P/E Ratio
$3.60
N/A
Revenue Growth
6.52
N/A
52 Week Low
$23.27
$4.16
52 Week High
$69.20
$14.45

Technical Indicators

Market Signals
Indicator
NBR
VIR
Relative Strength Index (RSI) 53.18 46.90
Support Level $49.00 $5.73
Resistance Level $53.74 $6.11
Average True Range (ATR) 2.81 0.43
MACD -0.56 -0.10
Stochastic Oscillator 37.50 19.17

Price Performance

Historical Comparison
NBR
VIR

About NBR Nabors Industries Ltd.

Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Share on Social Networks: